AstraZeneca PLC (AZN) Stock AnalysisAZNStock AnalysisAstraZeneca PLC

AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

AstraZeneca PLC (AZN) is a good buy right now, trading at $162.70 with a forward P/E of 16.23, indicating attractive valuation compared to its growth potential. The stock has shown a remarkable year-to-date change of +77.68% and a one-year change of +102.89%, reflecting strong performance. The recent acquisition of Zegfrovy for $600 million, with potential total commitments of $1.5 billion, demonstrates AstraZeneca's strategic growth plans in oncology, which could drive future revenue. However, the RSI is currently at 42.88, suggesting the stock is nearing oversold territory, which may present a buying opportunity. The main risk is the discontinuation of the lung cancer trial, which could affect investor sentiment and future earnings potential.

5 analysts cover AZN: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 213.64.